PFE

Pfizer Inc

OPPORTUNISTIC BUY Analysis generated 2026-10-04 Market data as of 2026-11-12 Market data 3 days old USD 28.83 Healthcare - Drug Manufacturers - GeneralAWAIT ENTRY

ACTIONABLEMethodology gates passed

Position levels

Currenttoday

USD 28.83

Buy <=wait / entry

USD 25.33

Trim >=take some off

USD 30.00

Thesis breakA dividend cut, a cancelled Metsera transaction, or a pivotal oncology readout f...

Scenario-weighted conviction

	Probability	Score	Contribution
Bull case	29%	100 / 100	29.0
Base case	50%	62 / 100	31.0
Bear case	21%	10 / 100	2.1
Weighted conviction			62 / 100 - OPPORTUNISTIC BUY

Top risks

M&A activity: Acquisition of Metsera (Sep 2025) for obesity and metabolic diseases
Strategic licensing deals: Exclusive global collaboration and license agreement with YaoPharma; global strategic collaboration with Innovent Biologics for oncology medicines
Earnings and guidance changes: Q2 FY26 EPS beat (+0.77 actual vs +0.68 estimate); reaffirmed 2025 EPS guidance, 2026 revenue guidance $59.5-62.5B and adjusted EPS $2.80-3.00

Read full report →

Research is for informational purposes only. Not financial advice. All analysis reflects the date of publication.